Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Adjuvant Therapy

Adjuvant Therapy

26

Pipeline Programs↗

29

Active Trials↗

15

Companies Involved↗

Adjuvant Therapy is an emerging landscape with 26 programs across 15 companies. The most active players are Nanjing Sanhome Pharmaceutical, Co., Ltd.. 12 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

46/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Nanjing Sanhome Pharmaceutical, Co., Ltd.

1 program

Pipeline

Programs by Phase

Preclinical2

Donafenib

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Pigment Solution Program

Dr.dr.Irma Bernadette, SpKK (K)

Phase 1

No programs

Phase 212

Tislelizumab

BeiGene

Durvalumab

AstraZeneca

Dual Antibody B

Second Affiliated Hospital, School of Medicine, Zhejiang University

Adjuvant Tislelizumab

Tianjin Medical University Cancer Institute and Hospital

Albumin Paclitaxel

Chipscreen Biosciences, Ltd.

Phase 312

Icotinib

Betta Pharmaceuticals Co., Ltd.

Antivascular Therapy

Fudan University

Rezivertinib

The First Affiliated Hospital of Guangzhou Medical University

Ensartinib

Xcovery Holdings, Inc.

Benmelstobart

Sun Yat-sen University

Approved

No programs

Analysis

Modality Breakdown

69%

Small molecule

18 of 26 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 100% of 26 pipeline programs.

Analysis

Trial Status

64

clinical trials

Unknown status22 · 34%

Recruiting18 · 28%

Completed6 · 9%

Not yet recruiting6 · 9%

Active, not recruiting5 · 8%

Terminated4 · 6%

Other3 · 5%

Clinical Trials

Trial Activity

64 trials

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Recruiting·GGuangdong Provincial People's Hospital·Phase 3·NCT06533384·310 enrolled

Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06936046·200 enrolled

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Recruiting·—·Phase 2·NCT05407519·40 enrolled

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Recruiting·NNuvation Bio Inc.·Phase 3·NCT07154706·180 enrolled

A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients

Recruiting·SSun Yat-sen University·Phase 3·NCT03561740·794 enrolled

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06939127·38 enrolled

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

Recruiting·SSun Yat-sen University·N/A·NCT06609876·108 enrolled

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

Recruiting·FFudan University·Phase 3·NCT05909332·764 enrolled

Tumor Regression Grade As Predictor of Adjuvant Therapy

Recruiting·FFujian Medical University Union Hospital·N/A·NCT06710665·400 enrolled

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06081673·72 enrolled

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Recruiting·—·Phase 2·NCT06863311·70 enrolled

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Recruiting·AAkeso·Phase 3·NCT05489289·570 enrolled

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06190639·31 enrolled

SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection

Recruiting·CCytocraft Biopharmaceutical Co., Ltd.·Phase 1·NCT07096882·22 enrolled

Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress

Recruiting·Ministry of Health, Saudi Arabia·Phase 2/3·NCT06026163·134 enrolled

Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)